Industry Overview

UK myocardial infarction market was valued at approximately $1.4 billion in 2025 and is projected to reach $2.3 billion by 2035, expanding at a CAGR of 5.5% during the forecast period from 2026 to 2035. This market includes a wide range of therapeutic and diagnostic solutions used in the management of acute myocardial infarction, such as pharmacological treatments, interventional cardiology devices, and advanced diagnostic technologies. In 2026, researchers from the University of Manchester Faculty of Biology, Medicine and Health reported significant progress in rapid diagnostic testing for acute coronary syndromes, including myocardial infarction. Their study demonstrated that high-sensitivity troponin assays combined with the T-MACS diagnostic algorithm allow clinicians to rule out heart attacks within a few hours, compared to traditional methods that could take up to three days. More than 30,000 patients in Greater Manchester have already benefited from these innovations, with many safely discharged on the same day, thereby improving healthcare efficiency and patient outcomes.

The growth of the market is largely driven by the rising prevalence of coronary artery disease, supported by aging demographics and lifestyle-related risk factors such as hypertension, diabetes, and obesity. In addition, advancements in minimally invasive procedures, particularly percutaneous coronary intervention (PCI), are significantly enhancing survival rates while reducing hospital stays. Furthermore, in April 2026, NHS England announced plans to provide the drug semaglutide (Wegovy) to over one million high-risk cardiovascular patients to lower the risk of heart attacks and strokes. Backed by recommendations from the National Institute for Health and Care Excellence, clinical evidence indicates that the drug can reduce major cardiovascular events, including myocardial infarction, by around 20%. These developments underscore continuous innovation across pharmaceutical and device segments, strengthening the overall myocardial infarction treatment landscape in the UK.

Market Dynamics

Drug Powerhouse Drives UK Heart Attack Treatment Market Growth

Pharmacological treatment continues to dominate the myocardial infarction market, fueled by the extensive use of antiplatelets, statins, and anticoagulants for both acute care and long-term prevention. Leading companies such as AstraZeneca and GSK plc are actively advancing cardiovascular drug innovation to enhance patient outcomes. In February 2026, GSK plc strengthened its position by acquiring 35Pharma Inc. for approximately $950 million, expanding its cardiopulmonary pipeline. The acquisition includes HS235, an investigational therapy targeting pulmonary hypertension and heart failure–related conditions. While not directly focused on myocardial infarction, the therapy addresses underlying cardiovascular dysfunctions linked to heart performance. This move reflects a broader strategic push toward innovative drug development in cardiovascular care. As a result, pharmacological therapies remain central to both immediate treatment and long-term management of heart attack patients in the UK.

AI-Powered Diagnostics Revolutionizing Heart Attack Detection

Diagnostics segment is emerging as the fastest-growing area in the myocardial infarction market, fueled by advancements in cardiac biomarkers and imaging technologies that enable earlier and more accurate detection. In March 2026, the European Society of Cardiology reported that artificial intelligence (AI)-based ECG interpretation significantly outperformed traditional diagnostic methods in identifying occlusive myocardial infarction. The study highlighted that AI markedly improves diagnostic accuracy, particularly in non-ST-elevation cases where timely detection is often challenging. By enhancing sensitivity and clinical decision-making, AI-driven tools help reduce delays in treatment initiation. Notably, the AI system achieved an impressive specificity of 99%, ensuring reliable identification of true positive cases. This advancement underscores a major shift toward data-driven and precision diagnostics in cardiovascular care. As adoption increases across healthcare systems, these innovations are expected to play a crucial role in strengthening early diagnosis and improving patient outcomes in myocardial infarction management.

Market Segmentation

• Based on treatment type, the market is segmented into pharmacological treatment, interventional treatment, and diagnostics.
• Based on device type, the market is segmented into coronary stents, catheters & guidewires, thrombectomy devices, and imaging catheters (IVUS, OCT).
• Based on end-user, the market is segmented into hospitals, cardiac care centers/cath labs, and emergency medical services (EMS).

UK Strengthens Heart Attack Care with Advanced Drug-Eluting Stent Evaluation

Coronary stents remain the most widely used devices in percutaneous coronary intervention (PCI), the gold-standard treatment for acute myocardial infarction in the United Kingdom. In May 2025, the published HealthTech guidance (HTG747) assessing drug-eluting coronary stents for coronary artery disease management. The evaluation reviewed multiple stents used within the National Health Service, focusing on clinical effectiveness, innovation, and cost efficiency to guide procurement decisions. Drug-eluting stents, designed to release antiproliferative drugs, help keep arteries open and reduce the risk of re-blockage. Their widespread use during PCI procedures plays a critical role in restoring blood flow and preventing myocardial infarction. The guidance reinforces the importance of evidence-based adoption of advanced cardiac devices. It also supports optimized patient outcomes while ensuring cost-effective healthcare delivery across the UK.

Market Players Outlook

The major companies operating in the UK myocardial infarction market include AstraZeneca, GlaxoSmithKline, Smith & Nephew, Abcam, and EKF Diagnostics, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In May 2025, Genedrive plc announced that its CYP2C19-ID Kit will be evaluated for use in patients with acute coronary syndrome (ACS), including myocardial infarction, as part of a UK-based clinical programme. The study, led by Manchester University NHS Foundation Trust in collaboration with the GUIDE PCI programme, aims to integrate rapid genetic testing into PCI procedures to guide antiplatelet therapy selection. The point-of-care test identifies CYP2C19 genetic variants within hours, enabling clinicians to determine whether patients will respond effectively to drugs like clopidogrel and personalize treatment accordingly.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the UK myocardial infarction market.
• Based on the availability of data, information related to new protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.